New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
07:47 EDTCG, JNJJNJ accepts $4B binding offer from Carlyle to acquire Ortho-Clinical Diagnostics
Johnson & Johnson (JNJ) announced that it has accepted the binding offer from Carlyle Group (CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4B, subject to customary adjustments. This acceptance was made after consultation with the relevant works councils and trade unions. The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions. :theflyonthe
News For JNJ;CG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
October 13, 2015
06:46 EDTJNJJohnson & Johnson announces $10B share repurchase program
Johnson & Johnson announced that its board has approved the repurchase of up to $10B of the company's common stock. The repurchase program has no time limit and may be suspended for periods or discontinued at any time.
06:45 EDTJNJJohnson & Johnson announces $10B share repurchase program
Subscribe for More Information
October 12, 2015
15:00 EDTJNJJohnson & Johnson October 96 straddle priced for 2% movement into Q3
Subscribe for More Information
14:56 EDTJNJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.45... Fastenal (FAST), consensus 47c... Del Frisco's Restaurant (DFRG), consensus 4c.
12:25 EDTJNJEarnings Watch: RBC says J&J Q3 results likely to beat expectations
Subscribe for More Information
11:58 EDTJNJJohnson & Johnson technical notes before earnings
Subscribe for More Information
October 9, 2015
17:07 EDTJNJJohnson & Johnson Chief Accounting Officer retires as planned
On October 9 , Stephen J. Cosgrove, Controller and Chief Accounting Officer of the Registrant retired, and upon Mr. Cosgrove's retirement, Ronald A. Kapusta became Controller and Chief Accounting Officer of the Registrant, as planned and previously reported by the Registrant on May 21.
08:30 EDTJNJBioNJ to hold a summit
Subscribe for More Information
07:37 EDTCGPrivate equity asset managers attractive, says Oppenheimer
Oppenheimer expects the private equity-based asset managers to report Q3 negative economic net income. However, Oppenheimer believes that such losses are "a fiction" created by accounting. Oppenheimer's analyst continues to believe that these companies have the best business mode he has sen in 30 years of covering financial stocks, and views the group as significantly undervalued. He expects the group's cash earnings to continue on an upward path, and says that Blackstone (BX), Carlyle Group (CG), and KKR (KKR) all had "significant realizations" in Q3 and have strong backlogs.
05:54 EDTJNJEli Lilly upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Vamil Divan upgraded Eli Lilly (LLY) to Outperform after his survey of 51 physicians suggested increasing use of the company's diabetes drug Jardiance. Jardiance is likely to drive near-term upside to Lilly while the company's pipeline is being underappreciated at current share levels, Divan tells investors in a research note. He raised his price target for shares to $105 from $89. The pharmaceutical giant closed yesterday down 24c to $83.75. The analyst also raised his sales estimates for Merck (MRK) and Johnson & Johnson (JNJ) following his physician survey.
05:17 EDTJNJJohnson & Johnson announces start of Ebola vaccine regimen trial in Sierra Leone
Subscribe for More Information
October 8, 2015
16:03 EDTJNJAduro Biotech receives milestone payment from Janssen for submitting IND
Subscribe for More Information
October 7, 2015
12:18 EDTCGCarlyle eyes small acquisitions with Japan buyout fund, Bloomberg says
Carlyle Group plans to use the nearly $1B in its third Japan buyout fund to buy family-owned firms and other mid-cap companies, Bloomberg reports, citing Tamotsu Adachi, the company's managing director and co-representative for Japan. In Tokyo, Carlyle often seeks family-owned companies with enterprise values of below $300M, the report says. Reference Link
11:32 EDTJNJLeerink medical supplies/devices analyst holds analyst/industry conference call
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson Q3 results likely to beat expectations, says RBC Capital
RBC Capital says that Johnson & Johnson's pharmaceutical prescriptions are tracking above its expectations this quarter, and the firm expects strong pharma results and cost-cutting measures to enable the company to beat Q3 expectations. The firm thinks the company could more aggressively deploy its balance sheet, creating a positive catalyst for the stock going forward. RBC keeps a $114 price target and Outperform rating on the shares.
07:34 EDTJNJAlliance for Regenerative Medicine to hold a meeting
Stem Cell Meeting on the Mesa is being held in La Jolla, California on October 7-9.
06:42 EDTJNJJohnson & Johnson volatility flat into Q3 and outlook
Subscribe for More Information
October 6, 2015
13:32 EDTJNJBiotechs plummet with TPP seen as industry negative
Biotechs are falling intraday after reports that the Trans-Pacific Partnership, or TPP, has language that the exclusivity period for bioligics, or drugs derived from a biological sources, would be eight years, less than the twelve years it is currently in the United States. WHAT'S NOTABLE: In the U.S., biologics are protected from competition by follow-on products for twelve years from the time they are first granted marketing approval by the U.S. Food and Drug Administration, a protection that is distinct from patent protection. Recent reports on the TPP suggest that the protection will last five years with an additional safety monitoring period of up to three years before a biosimilar can be registered, which would effectively be an eight year exclusivity period. ANALYST REACTION: Piper Jaffray analyst Joshua Schimmer, however, said the development is a "step forward," especially since it does not overrule the 12 years' exclusivity for the drugs in the U.S. While the sector asked for twelve years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argued. His top picks were Alexion (ALXN), Celgene (CELG), and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC), and Ignyta (RXDX) in the small-cap sector. Further, Schimmer stated that more names look "increasingly compelling" amid the selloff. NOTABLE DECLINERS: Alexion is lower by 2.53%, Celgene is down 4.32%, Amgen is declining 1.91%, Biogen (BIIB) is down 3.4%, and Gilead Sciences (GILD) is falling 2.22%. STOCKS TO WATCH: Other publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
October 5, 2015
06:54 EDTJNJJohnson & Johnson resumed with a Neutral at Piper Jaffray
Subscribe for More Information
October 4, 2015
19:07 EDTJNJCardinal Health sees Cordis acquisition adding more than 20c to FY17 EPS
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use